Analysis

3 Places The Allergan Tribal Deal May Face Pushback

By Matthew Bultman (October 12, 2017, 7:14 PM EDT) -- Allergan PLC's controversial attempt to shield patents for dry-eye drug Restasis from review at the Patent Trial and Appeal Board by making a deal with a Native American tribe has drawn intense scrutiny, amid concerns from groups including lawmakers and generic-drug companies. Here are three places where the deal will be closely examined....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!